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As pointed out by Henderson (1) in 1993,
one ofthe most dramatic features ofbreast can-
cer is the disparity in incidence rates between
highly westernized and nonwesternized coun-
tries. Women born and raised in the United
States are at least five times as likely to get breast
cancer as women born and raised in Japan. But
Japanese women increase their risk iftheylive in
rapidly westernizing Japanese cities or emigrate
and live in the United States. As is true with
coronary heart disease, differences in diet are
thought to be a major underlying factor in the
different incidence rates ofbreast cancer, partic-
ularly amongpostmenopausal women.
The hypothesis that differences in diet
can change breast cancer and heart disease
incidence in postmenopausal women is at
least, in part, proposed based on results
generated from studies on phytoestrogens.
Phytoestrogens are plant chemicals that
bind to the estrogen receptor and induce
many components of estrogen action
(2-10). The best known phytoestrogens are
diphenolic chemicals that belong to the
classes offlavonoids, isoflavonoids, and lig-
nans (2-10). These compounds are thought
to play a beneficial role in preventing breast
cancer. They may function as antiestrogens
or weak estrogens by competing with estro-
gens for binding to the estrogen receptor
(ER). However, we feel that it is also possi-
ble that some of these compounds may act
in an indirect fashion by inhibiting aro-
matase activity, resulting in a decrease in
the level ofestrogen in women. This aspect
may have been overlooked.
In estrogen-dependent breast tumors,
estrogens induce the expression of peptide
growth factors that are responsible for the
proliferative responses of cancer cells
(11,12). Aromatase, a cytochrome P450, is
the enzyme synthesizing estrogens by cat-
alyzing three consecutive hydroxylation
reactions converting C19 androgens to aro-
matic C18 estrogenic steroids (Fig. 1).
Because aromatase is the enzyme responsi-
ble for the synthesis of estrogens and
because estrogens have a major effect on the
development ofbreast cancer, an abnormal
expression of aromatase in breast cancer
cells or surrounding adipose stromal cells
may have a significant influence in breast
tumor maintenance and growth in breast
cancer patients. Cell culture and nude
mouse studies using aromatase-transfected
MCF-7 and T-47D cells (13-15) have
demonstrated that tumor aromatase can
play a role in breast cancer maintenance
and progression. It has also been suggested
that in situ produced estrogen plays a more
important role than circulating estradiol in
breast tumor promotion (16,17). Estrogen
synthesized by the tumor aromatase was
shown to stimulate breast tumor growth in
both an autocrine and a paracrine manner
(15). Aromatase-inhibitor therapy is a sec-
ond-line treatment for those who fail anti
estrogen therapy. Twenty to 30% of the
patients who fail antiestrogen treatment
respond to aromatase-inhibitor treatment.
Phytoestrogens have been reported to be
inhibitors of aromatase (18-22); therefore,
these chemicals may function as chemopre-
ventive agents by inhibiting aromatase/estro-
gen biosynthesis in postmenopausal women.
In this study, we have examined the interac-
tion ofeight flavone and isoflavone phytoe-
strogens with human aromatase and its
mutants by inhibition kinetic analysis and
computer modeling. Some of these com-
pounds such as chyrsin (5,7-dihydrox-
yflavone) inhibit aromatase with N values
similar to that of aminoglutethimide, an
aromatase inhibitor used clinically to treat
breast cancer. While phytoestrogens have
been reported to be inhibitors ofaromatase,
the molecular basis of their inhibition of
aromatase is not known.
During the past 5 years, using computer
modeling and site-directed mutagenesis, we
have evaluated a number of amino acid
residues that are thought to be present in the
active site and play a critical role for the
binding of the androgen substrate (23-30).
These aromatase mutants areveryvaluable in
determining the binding characteristics of
different aromatase inhibitors to the enzyme
by examining how mutations in the active
site of aromatase affect the binding of the
inhibitors, as indicated by changes in their
inhibition profiles (28-30). Recently, the
binding characteristics of seven aromatase
inhibitors were determined using the above
Figure 1. Aromatase converts androgens to estro-
gens.
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approaches (30). In this paper, we report the
inhibition profiles of eight phytoestrogens
on thewild-type aromatase and six mutants.
By analyzing these results together with
results generated previously with well-char-
acterized aromatase inhibitors (28-30),
information regarding the molecular basis of
the inhibition of aromatase by phytoestro-
gens was obtained. This information is very
important to further develop a strategy for
prevention and treatment of breast cancer
withplant chemicals such asphytoestrogens.
Materials and Methods
Materials. Unless otherwise indicated, the
phytoestrogens tested in this study were
purchased from Aldrich (Milwankee, WI)
or Calbiochem (La Jolla, CA). Dimethyl-
sulfoxide was obtained from Mallinckrodt
(Paris, Kentucky). [1 -3H(N)]-Androst-4-
ene-3,17-dione was purchase from New
England Nudear (Boston, MA). Progesterone
and NADPH (tetrasodium salt) were from
SigmaChemical Co. (St. Louis, MO).
Molecular modeling. The generation of
a three-dimensional model of human aro-
matase has been described previously (31).
The modeling of the binding of phytoe-
strogens in the active site was performed
using the program BIOGRAF, a molecular
modeling program marketed by Molecular
Simulations, Inc. (Waltham, MA). The
phytoestrogens were built using fragment
libraries supplied with the program. Partial
charges were assigned using the Q-
Equilibrate algorithm. The initial struc-
tures, most ofwhich were semirigid, were
flrst energy minimized to a root-mean-
square (RMS) force ofless than 0.001. The
resulting structures were subjected to 1
psec of molecular dynamics at 300 K, fol-
lowed by conjugate gradient minimization
to an RMS force ofless than 0.001.
The minimized phytoestrogen mole-
cules were then individually placed within
the active site ofthe aromatase model such
that overlap with the bound substrate was
optimal. Each inhibitor was again energy
minimized, but this time in the context of
the active site (indudes all residues within
10 A ofthe inhibitor). This optimized the
position ofeach inhibitor within the pock-
et, assuming that the pocket was rigid.
Finally, we repeated the minimizations,
assuming that residues within the active
site can move to better accommodate the
inhibitors (induced fit theory ofmolecular
interaction) to see if the results better
explain the inhibition binding data gener-
ated in our laboratory.
Stable expression and site-directed
mutagenesis experiments. Aromatase
mutant cDNAs were generated using a
PCR-based mutagenesis method, which was
described in a previous publication (30).
The mutant constructs were religated into
the mammalian expression vector, pHo-
Apr-1-Neo (32), through the engineered
Sal I and Hind III restriction sites. The
transfection procedure was the same as
described previously (33) except that the
selection process continued for 4 weeks
with stepwise increases ofG418 (Promega,
Madison, WI) up to a final dosage at 680
pg/ml. Six mutants, I133Y, I395F, 1474Y,
P308F, D309A, and T310S, were generat-
ed by this method (23,24,26,30) and used
in this study. The study was carried out
with the wild type- and mutant-expressing
Chinese hamster ovary (CHO) cells. The
expression of these enzyme mutants in
transfected CHO cells was confirmed by
enzyme activity measurement and western
blot analysis (or immunoprecipitation
analysis) (23,24,26,30). A detailed discus-
sion of the catalytic properties of these six
mutants has been published (30).
Other experiments. The aromatase
activity was determined by a 3H20 release
assay, as described by Zhou et al. (33). This
3H20 release assay for human aromatase
expressed in CHO cells was previously vali-
dated by the product isolation assay (33).
For the aromatase inhibition study, phytoe-
strogens were dissolved in dimethylsulfox-
ide and added during the assays with 100
nM [11-3H] androstenedione. In addition,
the inhibition profile studies were per-
formed using an in-cell method; the results
produced by the in-cell method have been
shown to be comparable to those deter-
mined using microsomal preparations of
aromatase and its mutants (30). The Kival-
ues for phytoestrogens were derived from
Dixon plots (1/v vs. [I]). These compounds
were shown to be competitive inhibitors of
aromatase with respect to the androgen sub-
strate. The Km values of the substrate for
the wild type and mutant aromatase were
needed for the calculation ofKA, and those
can be found in Kao et al. (30).
Results and Discussion
Active site model ofaromatase. Phytoestro-
gens such as flavones have been found to be
competitive inhibitors of aromatase with
respect to the substrate (18-22), suggesting
that these compounds probably bind to the
active site ofthe enzyme. Stronger evidence
for the binding ofthese compounds to the
active site ofaromatase was obtained from
difference absorption spectral studies. Kellis
and Vickery (18) reported that cx-naph-
thoflavone could displace androstenedione
bound to human placental aromatase and
induced a difference spectrum characteristic
ofthe conversion ofthe heme-iron from a
high-spin to a low-spin state. These authors
further suggested that thelow-spin nature of
a-naphthoflavone-enzyme complex indicates
the presence of an additional axial ligand to
theheme-iron, possiblytheC4-keto group.
Both we (30) and Graham-Lorence et
al. (34) have generated models of aro-
matase through an alignment ofthe amino
acid sequence ofthe human aromatasewith
those ofcytochromes P450cam, P450bm3,
and P450terp [whose X-ray structures have
been determined (35-37)] and homology
modeling by computer. The two models
from two laboratories are in a good agree-
ment except in the region between the C
and F helices. By examining the structures
ofcytochromes P450cam, P450bm3, and
P450terp, most residues participating in
the construction of the active site fall in
three regions, including the sequence seg-
ment between the B' and C helices, the I
helix, and the f4-2 strand close to the car-
boxy terminus. Among the amino acid
residues mutated in our laboratory, Ile-133
in the human aromatase is thought to be
located in the region between the B' and C
helices and predicted to form van der
Waals interactions with the f face ofthe C
and D rings ofthe steroid substrate (30).
In the I helix, there is a conserved threo-
nine (Thr) residue in all the known
cytochrome P450 structures except P450eryF
(38), and Thr-310 in aromatase is the con-
served residue. Thr-310 appears to be
involved in stabilizing the distortion in the I
helix by providing a hydrogen bond to the
carbonyl group ofalanine (Ala)-306; in addi-
tion, it may act as a proton donor during the
redox reactions (30). Furthermore, the
increased sensitivity ofthe mutant T310S to
several nonsteroidal aromatase inhibitors sug-
gests that, in the normal enzyme, the methyl
group ofThr-310 may be involved in steric
clashes with such inhibitors, somewhat reduc-
ing their binding affinity (30). The residue
adjacent to the conserved threonine residue is
an aspartic acidwhich is alsohighlyconserved
in cytochromes P450. Studies have suggested
that aspartic acid (Asp)-309 is an important
residue in the active site ofaromatase (24,34).
An Asp-309 to Ala mutation could cause a
partial collapse in the active site cavity that
reduces theabilityofall thestudiedinhibitors,
except aminoglutethimide (AG), to bind to
aromatase (30). AG is smallerthan the andro-
gen substrate, and the enhanced inhibition of
D309A may result from a tighter binding of
AG in an active sitecavityofreducedvolume.
In addition, a characteristic ofcytochrome
P450 structures is thedistortion in the central
region ofthe I helix with the formation ofa
deft in the region ofthe heme iron. In the
cytochrome P450cam-based model of aro-
matase, proline (Pro)-308 forms part ofthis
cleft. Interestingly, the aromatase mutant
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P308F was found to be more sensitive to
treatment by two steroidal inhibitors [4-
hydroxyandrostenedione (4-OHA) and 7a-
(4'-amino)phenylthio-1,4-androstadiene-
3,17-dione (7aAPTADD)] than the wild
typeenzyme (30).
Isoleucine (Ile)-474 in the carboxy ter-
minus ofaromatase corresponds to Ile-395,
an active site residue in cytochrome
P450cam, and is thought to be situated
around the lower edge ofthe B ring ofthe
androgen substrate in aromatase (30). Ile-
395 is in a region (residues 380-402) con-
served among aromatase of all species ana-
lyzed so far. The Km value of androstene-
dione for I395F was found to be signifi-
cantly larger than that ofthe wild-type aro-
matase (30), suggesting that the mutation
reduces the binding affinity ofthe substrate.
To study how flavone phytoestrogens
interact with aromatase, we investigated the
interaction ofeight phytoestrogens, induding
both flavones and isoflavones, with the wild-
type aromatase and six well-characterized
mutants, i.e., 1133Y, P308F, D309A, T31OS,
I395F, and 1474Y. Previous studies from our
laboratory have found that these mutations
significantly affect the binding of the sub-
strates and inhibitors of the enzyme
(23,24,26,30).
Inhibition ofaromatase byphytoestro-
gens. Figure 2 shows a computer-generated
model ofthe active site region ofaromatase
along with the substrate androstenedione.
The positions of Ile-133, Pro-308, Asp-
309, Thr-310, Ile-395, and Ile-474 are
highlighted.
The inhibition study involved four
flavones [chrysin (5,7-dihydroxyflavone),
7,8-dihydroxyflavone, baicalein (5,6,7-trihy-
droxyflavone), and galangin (3,5,7-trihy-
droxyflavone; also classified as a flavonol)],
two isoflavones [genistein (4',5,7-trihydroxy-
isoflavone) and biochanin A (5,7-dihydroxy-
4'-methoxyisoflavone)], one flavanone
[naringenin (4',5,7-trihydroxyflavanone)],
and one naphthoflavone (ax-naph-
thoflavone). The structures ofeight phytoe-
strogens are shown in Figure 3. The potency
of these compounds as aromatase inhibitors
has been determined according to their K.
values: a-naphthoflavone (2.2 ± 0.1 pM)
>chrysin (2.6 ± 0.1 gM) >naringenin (5.1 ±
0.2 IM) >7,8-dihydroxyflavone (10 ± 1 1iM)
>biochanin A (12 ± 5 pM) >galangin (95 ±
28 piM) >genistein (123 ± 8 pM). No inhibi-
tion by baicalein was observed with concen-
trations up to 50 pM. cx-Naphthoflavone is
the best aromatase inhibitor among all the
phytoestrogens studied [agreeing with find-
ings from other laboratories (17,20)], and its
Ki values are not different from those ofthe
aromatase inhibitor AG (1.37 gM).
Isoflavones are less effective than flavones in
inhibitingaromatase.
We evaluated the interaction ofphytoe-
strogens and aromatase mutants by compar-
ing their Ki values. The Ki values of seven
phytoestrogens to six aromatase mutants are
shown in Table 1. Among the four flavones
tested, chrysin is the best inhibitor. We
modeled the binding ofchrysin to the active
site ofaromatase based on the model for an
aromatase inhibitor, vorozole, because ofthe
resemblance in inhibition profiles with the
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Figure 2. Models ofthe predicted orientations of phytoestrogens in the active site of aromatase. (A) A computer-generated model of the active site region of aro-
matase along with the substrate androstendione. (B) The predicted orientation of chrysin (cyan), vorozole (yellow), and androstendione (orange), in the active site
of aromatase. (C) Predicted orientations ofa-naphthoflavone (red) along with chrysin (cyan). (D) Predicted orientations of biochanin A (red) and genistein (yellow).
Abbreviations: T310, threonine 310; 1133, isoleucine 133; 1395, isoleucine 395; 1474, isoleucine 474; P308, proline 308; D309, aspartic acid 309.
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an orientation inwhich theAand C rings of
flavone mimic rings C and D of a steroid
(see Fig. 2B). Bydoingso, thep-phenyl sub-
stituent (i.e., ring B) ofchrysin is oriented in
a similar position to that of the substrate's
ringAand is directed towards Asp 309. The
p-phenyl substituent tilts approximately 300
in reference to rings A and C ofthe flavone
(see Fig. 2B). The C4-keto group ofchrysin
points towards the heme prosthetic group
(Fig. 2C). Our computer modeling analysis
places the C4-keto group offlavones in an
area for the angular C19 of the androgen
steroid. Ibrahim and Abul-Hajj (19) report-
ed that a reduction ofthe C4-keto group to
a hydroxyl group greatly decreased the
inhibitory potency. As indicated above, the
low-spin nature of a-naphthoflavone-
enzyme complex led Kellis and Vickery (18)
to suggest the presence ofan additional axial
ligand to the heme-iron, possibly the
C4-keto group ofthe flavone. Such a model
also explains why polyphenols such as epi-
catechin and epigallocatechin, which are
present in tea and do not have a keto group
at the corresponding position, are not capa-
ble of inhibiting aromatase (Kao et al.,
unpublished observations; these compounds
were provided by C. S. Yang from the
College ofPharmacy, Rutgers University).
It has been reported that 5-hydrox-
yflavone is a less potent inhibitor of aro-
matase than flavone (19). The 5-hydroxy
group probably forms an intramolecular
hydrogen bonding with the 4-keto group
[indicated by nuclear magnetic resonance
(NMR) analysis (39)], weakening the inter-
action of the 4-keto group with the heme.
In a recently completed experiment, 7-
hydroxyflavone was found to be four times
more potent than chrysin (Kao et al.,
unpublished results). We feel that chrysin
Figure 3. Structures ofeightphytoestrogens.
resembles a seco-steroid that has an opened
B-ring and a homo D-ring. As suggested
previously (30), Pro-308 to Phe and Asp-
309 to Ala mutations modify the size ofthe
active site pocket, thus preventing the bind-
ing of chrysin as indicated by increases in
the Ki values (Table 1). Furthermore, the
increased sensitivity ofT310S to chrysin
suggests that in the normal enzyme this
methyl group may be involved in steric
dashes with the inhibitor, reducing its bind-
ing affinity somewhat. According to our
model, Ile-474 appears to be near the beta-
face and lower edge of chrysin's p-phenyl
ring. The increased potency for I474Y
might be due to favorable aromatic-aromat-
ic interactions between the phenyl sub-
stituent and the mutated residue. Ile-395 is
assigned to lie at the far end of the
hydrophobic pocket, and an aromatic-aro-
matic interaction may also explain the
increased potency by the mutation Ile-395
to Phe. Ile-133 has been proposed to be sit-
uated close to the heme in the current
model. Replacement by a bulkier residue
such as tyrosine maycause adisplacement of
the heme, probably exerting an indirect
effect on the bindings offlavones. A confor-
mational change in the active site by con-
verting Ile-133 to Tyr increases the relative
binding affinity ofchrysin, as indicated by a
decrease in theKivalue.
Baicalein, which differs from chrysin by
having an additional hydroxyl group at the
C-6 position, could not inhibit the wild-
type aromatase with concentration up to
50 pM. Ibrahim and Abul-Hajj (19) have
reported that 6-hydroxyflavone is a signifi-
cantly weaker inhibitor of aromatase than
flavone. These findings indicate that the
region around the C-6 position in the
active site of aromatase must be very
restricted. This may also explain why 4'-
amino-6-hydroxyflavone is a very ineffec-
tive inhibitor of aromatase (Kao et al.,
unpublished results). Because baicalein was
found to be a very poor inhibitor for the
wild-type aromatase, we did not pursue the
studywith mutants.
While 7,8-dihydroxyflavone was found
to be a less potent inhibitor than chrysin,
the inhibition profiles of this compound
were very similar to those ofchrysin except
Table I. K/valuessofseven phytoestrogens tothewild-type aromatase and six mutants
Enzymeform Chrysin 7,8-Dihydroxyflavone Galangin a-Naphthoflavone Naringenin Genistein BiochaninA
Wildtype 2.6±0.1 10±1 95±28 2.2±0.1 5.1±0.2 123±8 12±5
1133Y 0.3±0.1 86±25 3.1±1.3 0.8±0.1 4.2±1.3 16±2 5.9± 1.1
1395F 0.6±0.1 1.3±0.2 4.7±1.9 0.5±0.1 1.0±0.2 30±7 7.9±2.7
1474Y 0.06±0.02 0.3±0.1 5.9±1.1 1.2±0.1 0.5±0.1 24±2 1.0±0.1
P308F 3.2±0.3 13±2 52±12 0.6±0.1 7.5±0.3 42±19 24±4
D309A 13±3 40±21 22±4 2.8±0.5 40±7 92± 11 161±24
T310S 1.4±0.2 1.7±0.5 33±2 2.7±0.8 1.7±0.3 90±18 31±9
&Shown in pM.
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with the mutant I133Y (Table 1). The
results indicate that the binding affinity
decreases byhaving a hydroxyl group at the
C-8 instead of the C-5 position.
Furthermore, it is proposed that the pres-
ence of a hydroxyl group at the C-8 posi-
tion may push the A ring of the flavone
closer to heme or Ile-133, resulting in a
great increase ofthe resistance ofI133Y to
this flavone. As indicated in Figure 4, com-
puter modeling suggests another possible
orientation for the binding of flavone to
the active site ofaromatase, an orientation
in which rings A and C offlavone mimics
rings A and B ofa steroid and thep-phenyl
substituent is directed towards Ile-133.
However, this binding orientation is
thought to be unfavorable because the
mutant I133Y has been found to be more
resistant to 7,8-dihydroxyflavone than the
wild-type aromatase, whereas the same
mutant is more sensitive to chrysin than
the wild-type aromatase. Furthermore, in
the latter orientation, the C4-keto group
would be away from the heme, making it
difficult to explain the results associated
with this substituent (18,19). Because 7,8-
dihydroxyflavone has the same p-phenyl
substituent as chrysin, the relative respons-
es to P308F, D309A, T310S, and I474Y
were found to be similar to chrysin.
The results for galangin indicate that
the presence of a hydroxyl group at posi-
tion 3 of the flavone significantly reduces
its ability to bind to aromatase. Computer
modeling has revealed that the 3-hydroxyl
group is pointing to the I-helix and affects
the orientation ofthe phenyl substituent at
the C-2 position and may also interfere
with the interaction of the 4-keto group
with the heme. Two types of inhibition
profiles were observed for this compound;
three mutants with changes located on the
distal helix (P308F, D309A, and T310S)
exhibited regular dose-dependent profiles,
while the other three mutants as well as the
wild-type enzymes exhibited unusual
biphasic profiles (Fig. 5). The 3-hydroxyl
group of galangin and Thr-310 of the
enzyme are thought to be on the same side
ofthe beta-face ofthe flavone's ring-C. Ifa
larger accessible volume ofthe binding cav-
ity is obtained by removing the methyl
group ofthreonine at position 310, galan-
gin could bind better in the resulting active
site. Our inhibition studies have shown
that T31OS is more sensitive to galangin
than the wild-type aromatase at concentra-
tions less than 150 pM (Fig. 5). Contrary
to chrysin and other flavones, galangin
binds relatively better to the mutant
D309A than to the wild-type enzyme, sug-
gesting that galangin fits better in the
active site with a Asp-309 to Ala mutation.
The nature of the biphasic inhibition pro-
files is not known. There is a possibility
that galangin interacts with other proteins
in CHO cells. However, an interaction
with other proteins cannot explain why
biphasic inhibition profiles were found for
some but not all mutant forms of the
enzyme. At the present time, we cannot
explain these results adequately. As predict-
ed from the computer model, the increased
potency ofgalangin for I474Y may be due
to a favorable aromatic-aromatic interac-
tion between thep-phenyl substituent and
the mutated residue. Since both chrysin
andgalangin bear the sameA ring, the rela-
tive potency of I1 33Y to wild-type aro-
matase exerted by these compounds has
been found to be comparable in the two
compounds.
a-Naphthoflavone, but not P-naph-
thoflavone, is agood inhibitor ofaromatase.
a-Naphthoflavone has an additional benzo-
ring at the C-7 and C-8 positions ofring-A
of flavone. When superimposed over the
structure of chrysin, the C4-keto group of
a-naphthoflavone points closer to the
heme, implying a better fit in the active site
of aromatase (see Fig. 2C). A smaller KJ
value ofa-naphthoflavone for P308F than
the wild-type aromatase suggests further
that the binding orientation of a-naph-
thoflavone is slightly different from that of
chrysin. As discussed above, Kellis and
Vickery (18) observed that removal of the
C4-keto group of7,8-benzoflavone's pyra-
none C-ring to a furan ring totally dimin-
ished the inhibition ability, again indicating
that the 4-keto group is essential for the
inhibition of aromatase. P-Naphthoflavone
has a structure very different from a-naph-
thoflavone and does not fit in the active site
ofthe enzyme; this agrees with our inhibi-
tion experiment, which indicates that P-
naphthoflavone is a very poor inhibitor
(results not shown).
Naringenin is slightly less potent than
chrysin, but the inhibition profiles ofnarin-
genin were found to be similar to those of
chrysin. These results indicate that a conver-
sion of C2, C3 double bond to a single
bond has only a small effect on its binding
when compared to chrysin. In fact, the C2
atom in naringenin is a chiral center. Our
computer modeling has revealed that only
the S-configuration isomer can bind to the
active site. Therefore, the observed Ki values
might originate from a racemic mixture and
the actual Ki values for the S-configuration
isomer may be lower than those shown in
Table 1. However, the presence ofa single
bond between the C-2 and C-3 positions
does slightly modify the conformation of
ring C (as shown by the computer model-
ing), explainingwhytherewas an increase in
the K; value for I133Y by comparing it to
that ofchrysin. On the otherhand, the pres-
ence ofa4'-hydroxyl group has only a small
influence on the binding ofthe compound,
as indicated by similar inhibitory profiles as
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Figure 4.Two possible orientations offlavonesthat can fit intothe proposed active site pocketof aromatase.
Figure 5. Inhibition profiles ofwild-type (WT) aro-
matase and six mutants bychrysin (A) and galan-
gin (B) as determined bythe3H20 release assay
(see Materials and Methods).
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Figure 6. Aschematic presentation ofstructural requirementsforflavone and isoflavone phytoestrogens
to bind tothe active site of aromatase and tothe estrogen receptor(ER).
chrysin for the mutants P308F, D309A, and
T310S.
Our computer modeling reveals that
isoflavones may enter the active site pocket
in a similar way as flavones in that ring B is
positioned near the distal helix and the C4-
keto group is pointing towards the heme
(see Fig. 2D). Computer modeling suggests
that the pocket on the distal helix side may
be more compact or rigid so that ring B of
chrysin and the two isoflavones have to be
held at about the same position. In contrast,
the opposite side ofthe pocket is compara-
tively spacious (e.g., a-naphthoflavone
binds stronger in the active site of aro-
matase) and therefore allows the benzopyra-
none rings of these compounds relatively
free movement. Among these compounds,
the C4-keto group of genistein is the far-
thest from the heme as seen in the model
(Fig. 2D), in agreement with its poor
inhibitory potency. The results obtained
from inhibition profile studies indicate that
the binding of genistein is improved by
conformational changes upon mutations in
the region Pro-308 to Thr-310. Its binding
was also improved by Ile-474 to Tyr, Ile-
133 to Tyr, and Ile-395 to Phe mutations.
Interestingly, by having a methoxy rather
than a hydroxyl group at the C4' position,
biochanin A is a relatively better inhibitor
of aromatase than genistein. Computer
modeling suggests that the phenyl sub-
stituent of biochanin A is almost 900 rela-
tive to the plane of chrysin's ring B (Fig.
2D), explaining why the binding affinity of
biochanin A was found to decrease in
mutants P308F, D309A, andT31OS.
Flavone structure-activity studies from
other laboratories (18-21) and our present
study have revealed the structural features
for flavone and isoflavone phytoestrogens
to inhibit aromatase. By evaluating the
interaction of eight phytoestrogens with
the wild-type aromatase and six mutants by
computer modeling and inhibition profile
analysis, we have obtained further informa-
tion regarding how phytoestrogens bind to
the active site ofaromatase. Figure 6 sum-
marizes our current knowledge as to how
flavones bind to the active site of aro-
matase. These compounds bind to the
active site in an orientation such that their
A and C rings mimic rings D and C ofthe
steroid, respectively. The C4-keto group
points to the heme prosthetic group. The
presence ofa 5-hydroxy group reduces the
binding affinity, probably by forming a
hydrogen bond with the 4-keto group. 7-
Hydroxy- and 8-hydroxy-containing
flavones are reasonable inhibitors of aro-
matase. The C-6 position offlavones is sit-
uated in a very restricted area; therefore,
any flavones that have a C-6 substituent
cannot bind to the enzyme. Furthermore, a
3-hydroxy group significantly changes the
orientation of ring B, resulting in a large
decrease in the ability to inhibit aromatase.
Isoflavones such as genistein and daidzein
have the 4'-hydroxyphenyl group at posi-
tion C-3, greatly reducing the ability to
bind and inhibit aromatase. These
isoflavones cannot bind to aromatase in an
orientation in which rings A and C mimic
rings A and B ofthe steroid because the 4'-
hydroxy group will be situated in the area
equivalent to the C-6 position in flavones.
While it is possible that isoflavones without
the 4'-hydroxy group may inhibit aro-
matase, such compounds are not yet avail-
able for our investigation. Ongoing
research in this laboratory will evaluate the
effect ofthe hydroxy substituents ofring B
on the ability to inhibit aromatase.
The binding orientation of flavones
and isoflavones in relation to steroids in the
active site of aromatase is different to that
proposed for their binding to the estrogen
receptor (ER) (40,41). For ER, isoflavones
were found to be better ligands than
flavones, and rings A and C of isoflavones
were thought to mimic rings A and B of
estrogen. Furthermore, a 4'-hydroxy group
is thought to be required to bind ER effec-
tively (see Fig. 6). By using a yeast estrogen
system (YES) in which yeast cells were co-
transformed with the human estrogen
receptor (hER) and two copies ofan estro-
gen response element (ERE) linked to the
lacZ gene, Collins et al. (42) recently
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examined the agonist/antagonist activity of
various flavone and isoflavone phytoestro-
gens. The abilities of these compounds in
competing with [3H] 17p-estradiol for
binding to the recombinant hER were also
measured. The IC50 values (i.e., the con-
centration of the ligand competitor at
which the binding of radiolabeled 17p-
estradiol to the hER was reduced to 50%)
for coumestrol, genistein, biochanin A,
chrysin, and naringenin were determined as
0.01 pM, 2.0 pM, 6.0 pM, 33 pM, and 45
pM, respectively (42). The results indicate
that isoflavones such as genistein and
biochanin A bind to ER 5-10 times
stronger than flavones such as chrysin and
flavanones such as naringenin. Therefore,
in the present study, we reveal the different
structural features for phytoestrogens bind-
ing to aromatase and estrogen receptor.
We feel that this investigation has
demonstrated the utility of a combined
approach, which involves computer model-
ing, site-directed mutagenesis, and
inhibitor profile analysis using structurally
related inhibitors in a molecular characteri-
zation of an inhibitor binding site. Since
we have found that flavones are known to
be competitive inhibitors of NAD(P)H:
quinone acceptor oxidoreductase with
respect to NAD(P)H (43), it is possible
that these compounds also inhibit
NADPH-cytochrome P450 reductase.
However, we feel that this possibility is
unlikely, or at least the cytochrome P450
reductase inhibition does not play a major
role here because the inhibition profiles do
vary for different aromatase mutants.
Phytoestrogens such as flavones,
isoflavones, and flavanones are widely pre-
sent in the plant kingdom with the excep-
tion of algae, fungi, and hornworts (44).
These compounds are found in all parts of
the higher plants: roots, stems, leaves, flow-
ers, pollen, fruit, seeds, wood, and bark. For
example, chrysin is commonly found in
flowers such as the passion flower (45); the
genus Citrus is especially rich in flavanones
such as naringenin (46); and genistein and
biochanin A are known to be present in soy-
bean extracts (47). Adlercreutz et al. (48)
reported that in some vegetarian women
plasma genistein concentrations could be as
high as 0.1 pmol/l as determined by reverse
isotope dilution gas chromatography-mass
spectrometry. Adlercreutz et al. (49) have
also estimated that the plasma level ofgenis-
tein in people on a high soy-containing diet
is 1-4 pmol/l. Barnes (50) has made the fol-
lowing calculation: A person who consumes
35 g/day ofsoybeans (the average amount
consumed by the Taiwanese) has an intake
of -50 pg (185 pmol) of genistein; if we
assume that genistein equilibrates with total
body water (56 liters), the equilibrium plas-
ma concentration would be 3.3 pmol/l.
While there has not been an extensive exam-
ination ofthe concentrations ofvarious phy-
toestrogens in our body fluids, it is estimat-
ed that the overall concentration of all
flavones and isoflavones in circulation is in
the micromolar range. In our study, some of
the compounds are found to inhibit aro-
matase with JK values in the micromolar
range.
The present study is an in vitro study.
The effects could be different in vivo due
to metabolic conversion processes. Cell cul-
ture and animal studies including these
chemicals have been initiated in our labora-
tory. While the in vivo studies are critical
for a better understanding ofthe action of
phytoestrogens on estrogen biosynthesis,
the present study provides a molecular
basis regarding the binding nature and
structural requirements of phytochemicals
to inhibit aromatase.
Since the Women's Health Initiative is
carrying out a study to test the hypothesis
that a diet high in fruits and vegetables will
lower breast cancer incidence in post-
menopausal women, we anticipate that our
study ofphytoestrogens will generate infor-
mation regarding which phytoestrogens are
able to control estrogen biosynthesis. This
will help to determine which fruits and
vegetables, those containing proper phytoe-
strogens, should be included in a diet for
postmenopausal women.
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